Abbott announced partnerships with diabetic tech companies BeatO, Sugar.fit, PharmEasy, GOQii, 1MG, and Zyla on Tuesday.
The project includes Health, Healthifyme, and Fitterfly, according to the business.
Abbott said it hopes to reach 8 million diabetics through these partnerships, including 6.5 million through PharmEasy and 1MG.
Personalized lifestyle and treatment interventions help persons with diabetes accomplish comprehensive glucose control objectives, the company said.
"Over time, research and collaboration have simplified and enhanced diabetes management. New diabetic technology allows for more accurate and informed decisions "Abbott's Diabetes Care General Manager, Kalyan Sattaru, noted.
He said that combining Abbott's FreeStyle Libre with BeatO's app ecosystem will provide consumers accurate data and actionable insights to better manage their blood glucose levels.
"We are always aiming to make diabetes care more efficient and convenient for our members," he added.
To treat chronic metabolic problems, Sugar.fit's co-founder and CEO Madan Somasundaram claimed that the company's objective is to empower people with chronic ailments.
"A very consumer-centric data-driven digital health experience helps millions of Indians manage and reverse diabetes," he added.
India has the world's second-highest diabetes rate.
Diabetes patients in India are cutting back on doctor visits owing to the epidemic, and less than half of those with diabetes have a home blood glucose monitor.